Tocilizumab
Tocilizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma、Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
29 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Hoffmann-La Roche
- Genentech, Inc.
- Regeneron Pharmaceuticals
- Assistance Publique - Hôpitaux de Paris
- Merck Sharp & Dohme LLC
- Insel Gruppe AG, University Hospital Bern
- Janssen Research & Development, LLC
- SCRI Development Innovations, LLC
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、比利时、法国、Israel、意大利、荷兰、South Korea、西班牙、英国、加拿大、丹麦
正在招募患者的 Tocilizumab 研究
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
I 期 / II 期招募中美国澳大利亚比利时法国NCT03564340Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
II 期招募中法国NCT06381661A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
II 期 / III 期招募中加拿大丹麦法国GreeceNCT07570173PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
II 期招募中瑞士NCT06430736A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
II 期招募中美国Argentina澳大利亚法国NCT07589634A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
I 期 / II 期招募中美国澳大利亚Brazil中国NCT05533775To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
I 期招募中法国西班牙NCT07629583A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
II 期招募中美国NCT07637578A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
III 期招募中美国澳大利亚Brazil加拿大NCT06084936Neutralizing Interleukin (IL)-6
II 期招募中美国NCT07493317Plan Development for Giving Teclistamab in the Outpatient Setting
IV 期招募中加拿大NCT06251076Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
II 期招募中美国NCT05972135Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
III 期招募中中国NCT07509645Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
不适用招募中美国加拿大NCT03511118Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
I 期 / II 期招募中中国NCT07467863RA-PRO PRAGMATIC TRIAL
III 期招募中美国加拿大NCT04692493TCR1188-ABC Cells in KRAS-mutated Cancers
I 期招募中美国NCT07594067Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
II 期招募中美国NCT05846789Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
II 期招募中美国NCT07138898Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
I 期招募中美国NCT06016179ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
II 期招募中美国澳大利亚加拿大NCT05233397A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
I 期 / II 期招募中美国ArgentinaChile中国NCT07227597A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
II 期招募中美国NCT06859424A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
I 期招募中美国澳大利亚中国法国NCT05091424
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。